Advanced Biochemical Threats: The Role of Genetic Engineering in Bioterrorism and Countermeasures

Introduction

The rise of bioterrorism as a global threat has prompted increased scrutiny and research into the use of biological agents for hos- tile purposes. Bioweapons--biological agents such as bacteria, viruses, or toxins--are intentionally used to cause harm to hu- mans, animals, or plants. These agents can spread rapidly, causing widespread disease and panic, and their use in warfare or terrorism poses significant risks to public health and safety [1,2]. Biological weapons are defined as pathogens or toxins deliberately deployed to inflict disease or death on a large scale. Historically, the use of biological agents dates back to ancient times when adversaries poisoned wells or spread diseases to weaken enemies [3]. In the 20th century, advances in microbiology and genetics transformed the field of bioweapons, making them more potent and difficult to detect [4,5]. Notable historical instances include the use of anthrax and plague in warfare, and the development of sophisticated bio- weapons programs during the Cold War [6-9].

In recent decades, the threat of bioterrorism has escalated due to ad- vancements in genetic engineering and synthetic biology. The abil- ity to manipulate genes and create novel pathogens has increased the potential for bioweapons to be used in both state and non-state actor scenarios [10]. For instance, the 2001 anthrax attacks in the United States demonstrated the potential for bioweapons to cause widespread fear and disruption, even though the attacks were rel- atively limited in scope [11,12]. Genetic engineering, particularly techniques such as CRISPR/Cas9, has revolutionized molecular biology and biotechnology. These advancements allow for pre- cise modifications of the genomes of various organisms, including pathogens. While these technologies offer significant benefits for medicine and agriculture, they also pose risks if misused [13]. The potential to create genetically engineered bioweapons with en- hanced virulence, drug resistance, or novel properties underscores the need for stringent biosecurity measures and ethical oversight [10,14].

The outbreak of COVID-19, caused by the novel coronavirus SARS-CoV-2, has sparked debates about its origins and potential as a bioweapon. Theories range from natural zoonotic transmis- sion to accidental release from a laboratory [15,16]. While most scientific evidence supports a natural origin, some speculative theories suggest the virus could be a product of genetic engineer- ing [17,18]. The World Health Organization and various scientific studies have largely refuted the bioweapon theory, emphasizing the need for continued research to understand the virus's origins and mitigate future risk [19]. This study aimed to provide a com- prehensive analysis of bioweapons, focusing on the history, current trends, and implications of genetic engineering. It also examined the COVID-19 pandemic in the context of bioweapon theories, evaluating the scientific evidence and implications for future bios- ecurity. By synthesizing current research and expert opinions, this review seeks to enhance understanding and inform strategies for preventing and mitigating bioterrorism.

Methodology

Literature Search Strategy

A comprehensive literature search was conducted to gather rele- vant information on the use of bioweapons, genetic engineering, and the COVID-19 pandemic. The following databases were uti- lized: PubMed (for peer-reviewed biomedical and life sciences lit- erature), Google Scholar (for grey literature and a broader search), JSTOR (for historical and theoretical perspectives), and Web of Science (for multidisciplinary research and citation tracking).

The search strategy included combinations of the following key- words: "bioterrorism," "bioweapons," "genetic engineering," "CRISPR/Cas9," "SARS-CoV-2," "COVID-19 origin," "bioweap- on theory," and "biosecurity measures."

Inclusion Criteria:

• Peer-reviewed journal articles.

• Publications from the last two decades to ensure relevance.

• Articles in English or with English translations available.

• Studies providing empirical data, theoretical insights, or case studies relevant to bioweapons and genetic engineering. Exclusion Criteria:

• Non-peer-reviewed articles and opinion pieces.

• Publications with insufficient data or methodological rigor.

• Articles not directly related to the core topics of the review.

Data Extraction and Analysis

Data were extracted from selected articles focusing on the use and history of bioweapons, genetic engineering techniques and their applications, theories on the origin of COVID-19, including lab- based and natural origin theories. Opinions and evidence regarding COVID-19 as a potential bioweapon were also involved. Compar- ative tables were created to synthesize data on different origin the- ories of COVID-19 and opinions on its potential as a bioweapon. Trend analysis was utilized in identifying patterns and trends in bioweapon research, including advancements in genetic engineer- ing and biosecurity measures. Critical evaluation was used to as- sess the credibility and relevance of the sources, noting any biases or limitations.

Case Studies and Real-World Examples

Case studies were reviewed to provide real-world context. Recent instances of bioterrorism and biosecurity breaches, historical and contemporary examples of bioweapons use, relevant incidents in- volving genetic engineering and its misuse were reviewed. The sources for case studies were reports from health organizations (e.g., WHO, CDC), government and intelligence agency publica- tions, peer-reviewed case studies and reviews from credible jour- nals.

Synthesis and Presentation

Information was synthesized to address key themes and questions such as the effectiveness and history of bioweapons, advances and potential risks of genetic engineering technologies, and the validity and implications of COVID-19 origin theories. Findings were organized into: Comparative tables summarizing evidence and opinions, and narrative summaries that contextualize findings within current scientific and geopolitical discussions.

Discussion

Table 1 shows that a wide range of biological agents, such as Ba- cillus anthracis, Influenza virus, and botulinum toxins, are widely acknowledged as potential bioweapons. These pathogens are high- ly lethal, rapidly transmissible, and can be delivered through mul- tiple routes such as air, water, and food supplies. Additionally, the data reflects that genetically engineered pathogens—particularly through recombinant DNA technology—pose even greater threats due to their potential for enhanced drug resistance, evasion of im- mune responses, and improved stability in the environment.

Bacillus anthracis, with its three key toxins (Protective Antigen, Edema Factor, and Lethal Factor), is highlighted as a potent bio- weapon. Its genetic modification for antibiotic resistance, as demonstrated in some historical examples, further enhances its danger, making it an ideal candidate for bioterrorism [20]. Influ- enza virus, the causative agent of Influenza, can be engineered to resist multiple antibiotics, making outbreaks difficult to contain. The historical data from Madagascar in 1995 illustrates how the introduction of multidrug-resistant plasmids into these pathogens significantly heightened their bioweapon potential [21,22].

                                        Table 1: Types of Bioweapons and Historical Use

Genetic engineering has played a pivotal role in enhancing the virulence and transmissibility of biological agents (Table 2). The analysis of genetically engineered pathogens indicates an alarming trend in the use of molecular techniques to increase the potency of these organisms. For instance, Francisella tularensis, the bacteri- um responsible for tularemia, was altered by inserting a gene en- coding beta-endorphin to produce confusing symptoms in victims Borzenko et al., 1993. The manipulation of genes in this manner makes diagnosis more difficult, delaying treatment and contain- ment. Such findings illustrate the sophisticated use of genetic en- gineering for offensive purposes.

Furthermore, the insertion of antibiotic resistance genes into bac- teria like Bacillus anthracis and Yersinia pestis demonstrates how bioweapons can evade existing treatment protocols. This height- ens the global risk of large-scale infections that may be uncontrol- lable due to the lack of effective antibiotics.

                                Table 2: Advances in Genetic Engineering and Potential Bioweapon Applications

The COVID-19 pandemic has brought renewed attention to bioweapon theories, including speculation about the origins of SARS-CoV-2 (Table 3). This study evaluated evidence regarding the natural versus laboratory origins of the virus and its implica- tions for biosecurity. The majority of scientific evidence supports a zoonotic origin for SARS-CoV-2, with bats and other wildlife as potential reservoirs. However, concerns about laboratory accidents and biosecurity breaches have been raised, particularly due to the virus’s rapid spread and severity [23,17]. Despite speculative the- ories, current research and expert consensus suggest that while the virus’s origins warrant further investigation, there is no substantial evidence to classify it as a bioweapon [18,24].

                                               Table 3: COVID-19 Origin Theories and Evidence

This study has provided a comparative view of bioterrorism in- cidents globally and in Africa, highlighting the increasing use of biological weapons (Table 4). While documented cases of bioter- rorism in Africa are sparse compared to other regions, there is sig- nificant concern over terrorist groups like Boko Haram and their potential access to bioweapons. The increasing sophistication of such groups and their international affiliations suggest that Africa could be at high risk if bioweapons are utilized. This geographical analysis shows that while Western nations have focused heavily on bioterrorism defense, the lack of preparedness in African countries may leave them vulnerable to devastating bioterrorism attacks. The review highlights the need for stronger defensive measures, including improved surveillance and biodefense infrastructure.

In Ethiopia, historical instances of bioweapon use are minimal, with most references relating to natural outbreaks rather than deliberate acts. However, ongoing internal conflicts and limited surveillance capacities create a potential vulnerability to bioter- rorism, especially in volatile regions where state control is weak. Although infrastructural and technical capabilities for bioweapon development are limited, regional instability could create opportu- nities for non-state actors to exploit biological agents, particularly through rudimentary or externally sourced methods. Ethiopia has initiated regional biosecurity and emergency response plans, yet these efforts are often underfunded and dependent on international support.

Nigeria faces a more pronounced threat. The presence of organized extremist groups such as Boko Haram and ISWAP (Islamic State West Africa Province), combined with ongoing internal conflict, elevates the risk profile. These groups may theoretically consider biological agents as terror tools due to their potential for mass dis- ruption. However, their current tactics focus more on conventional methods—bombings, kidnappings, and armed assaults—largely due to lower cost, accessibility, and reliability compared to bio- weapons. The development or use of bioweapons requires scien- tific expertise, access to pathogens, laboratory infrastructure, and knowledge of safe handling procedures—all of which are likely beyond the current capacities of such groups. Nevertheless, Nige- ria’s high population density and limited public health infrastruc- ture heighten the potential impact of a biological attack, making improved surveillance and international cooperation crucial com- ponents of its prevention strategy.

South Africa, despite having no significant history of bioweapon use, possesses advanced industrial and scientific infrastructure that could, in theory, be repurposed for biological weapons production. The country’s developed economy and technological base make it more susceptible to internal misuse or cyber-biothreats, partic- ularly if rogue actors gain access to research facilities. However, South Africa maintains strict biosecurity protocols and regulatory oversight, which serve as strong deterrents. Its historical engage- ment with global non-proliferation agreements further reinforces its commitment to preventing misuse of biological materials. Ad- dressing the feasibility of bioterrorism in these contexts, it is es- sential to note that the development and deployment of biological agents is not only technically complex but also risky for the per- petrators. Improper handling can lead to self-infection or uncon- trollable spread, posing a threat to both users and unintended pop- ulations. Moreover, terrorist groups may often find conventional methods of attack more accessible, cost-effective, and symbolical- ly powerful than biological alternatives.

                                                Table 4: Comparative Analysis of Bioweapon Threats in Africa

Table 5 outlines five key defensive measures against bioweap- ons—Decontamination, Detection, Prevention, Protection, and Treatment—each contributing to a layered approach to mitigating the risk and impact of bioterrorism. Decontamination involves methods used to neutralize or remove biological agents from con- taminated environments. Common techniques include the use of chemical disinfectants (e.g., bleach solutions), thermal deactiva- tion through high heat, and ultraviolet (UV) radiation. These strat- egies are crucial for long-term safety, especially after a confirmed biological incident. For example, following the 2001 anthrax at- tacks in the United States, extensive chemical decontamination of affected mailrooms and offices was required. However, the effec- tiveness of decontamination depends heavily on timely application and environmental factors.

Detection systems are essential for the rapid identification of bio- weapon exposure, enabling timely responses. Notable examples include:

• SMART (Sensitive Membrane Antigen Rapid Test), which de- tects specific pathogens quickly in field conditions,

• JBPDS (Joint Biological Point Detection System), used by the U.S. military for real-time biological monitoring,

• BIDS (Biological Integrated Detection System), a vehicle-mount- ed system for broader environmental surveillance.

While these systems represent technological advancements, their effectiveness varies. Some offer rapid results but are limited in pathogen range or sensitivity, while others are more comprehen- sive but slower, highlighting the need for continued development.

Prevention refers to proactive strategies aimed at reducing the like- lihood of bioweapon development or deployment. This includes international legal frameworks such as:

• The Biological Weapons Convention (BWC) of 1972, which pro- hibits the development, production, and stockpiling of biological weapons,

• The United Nations Security Council Resolution 1540 (2004), which obligates member states to prevent non-state actors from acquiring WMDs, including bioweapons,

• Ongoing intelligence and biosurveillance efforts led by agencies like the WHO and Interpol.

While these treaties and initiatives contribute to global norms against bioweapons, enforcement and compliance remain chal- lenges, especially in politically unstable regions. Protection mech- anisms aim to shield individuals and communities during a biolog- ical event. This includes personal protective equipment (PPE) such as gas masks, biosafety suits, and filtration systems. These mea- sures are particularly valuable for first responders and medical per- sonnel, providing immediate, albeit temporary, protection against airborne or contact-spread agents. However, their effectiveness is contingent on correct usage, maintenance, and availability during emergencies.

Treatment encompasses medical interventions such as vaccines, antiviral medications, and antibiotics. For example, the anthrax vaccine and ciprofloxacin (an antibiotic) were used effectively during the 2001 anthrax incidents. Timely diagnosis and access to appropriate countermeasures are critical for treatment success. In some cases, stockpiles like those maintained by the U.S. Stra- tegic National Stockpile (SNS) offer rapid deployment of medical supplies during outbreaks, though such infrastructure is unevenly distributed globally.

                                                 Table 5: Defensive Measures against Bioweapons

The potential use of biological agents in bioterrorism presents sig- nificant risks to global health, security, and stability. This study has examined various aspects of bioterrorism, focusing on the biochemistry of potential bioweapons, genetic engineering impli- cations, recent cases, and the ongoing debate about the origins of COVID-19.

Biochemical Mechanisms and Genetic Engineering

Bioweapons, including bacteria, viruses, and toxins, exploit bio- logical mechanisms to inflict harm. Bacillus anthracis, the caus- ative agent of anthrax, secretes three key proteins—protective antigen (PA), edema factor (EF), and lethal factor (LF)—that col- lectively contribute to its virulence [7,25-26]. The genetic engi- neering of B. anthracis, particularly with drug-resistant properties, poses a severe threat due to the potential for untreatable infections [11,22,27-28]. Similarly, Yersinia pestis, the pathogen responsible for plague, has been genetically modified to resist multiple antibi- otics, further complicating treatment and control measures [29].

The advent of recombinant DNA technology has significantly ad- vanced the capabilities of bioweapons. Genetic engineering can enhance the virulence, transmissibility, and resistance of patho- gens, making them more formidable threats [10,30]. For instance, the modification of ricin toxin to increase its potency and resis- tance underscores the potential dangers associated with biotechno- logical advancements [31-33].

Recent Cases of Bioterrorism

Recent global and regional incidents highlight the persistent threat of bioterrorism. Although there have been no confirmed bioter- rorist attacks in Nigeria, the country remains vulnerable to such threats due to its geopolitical instability and the activities of mil- itant groups like Boko Haram (James et al., 2022). The potential for bioterrorism in Nigeria is exacerbated by the ongoing conflict and limited resources for bioterrorism prevention and response [34,35]. Globally, incidents such as the 2001 anthrax attacks in the United States demonstrate the real and present danger of bio- weapon utilization Hughes and Gerberding., 2002. These attacks not only caused widespread fear but also exposed vulnerabilities in public health preparedness and response systems.

COVID-19 and Bioterrorism Debate

The debate over the origins of SARS-CoV-2, the virus responsi- ble for COVID-19, continues to be a topic of significant interest. While the World Health Organization (WHO) has largely dis- missed the theory that COVID-19 is a bioweapon, the possibility of laboratory manipulation remains under investigation [36,18]. Genetic analysis of SARS-CoV-2 has revealed similarities with other coronaviruses, leading some to speculate about potential engineering or recombination events [37-39]. However, evidence supporting deliberate genetic modification is currently insufficient, and the prevailing view is that SARS-CoV-2 emerged from natural processes.

Defensive Measures and Future Directions

Effective defensive measures against bioweapons require a multi-faceted approach, including prevention, protection, detec- tion, treatment, and decontamination. International treaties and disarmament efforts play a crucial role in mitigating the risk of bioweapons proliferation [40]. Enhanced surveillance systems, improved healthcare infrastructure, and advanced research in vac- cine and therapeutic development are essential for combating po- tential bioterrorism threats [41]. Moving forward, there is a need for greater international collaboration and investment in bioterror- ism defense. Governments and scientific communities must work together to strengthen regulations, improve detection technolo- gies, and ensure transparency in biodefense programs [42]. The potential for misuse of biotechnology underscores the importance of maintaining stringent oversight and fostering global coopera- tion to safeguard against the proliferation of bioweapons.

Conclusion

While all bioweapon types pose significant threats, their strate- gic use has varied according to context, intent, and technological capability. Bacterial and viral agents are suited to mass-casualty scenarios, while toxins offer precision lethality. Understanding historical applications aids in anticipating future threats and guid- ing preparedness efforts. While each the multi-tiered defensive frameworks against bioterrorism offers value, their success hinges on the integration of technology, international cooperation, public health readiness, and robust policy enforcement. A more nuanced understanding of these tools—alongside investments in educa- tion, infrastructure, and interagency coordination—is essential for strengthening global biodefense capabilities. Bioterrorism poses varied levels of threat across African countries but these risks are shaped by local factors such as political stability, access to tech- nology, public health infrastructure, and the presence of violent non-state actors. Current preventive measures show promising di- rection but require enhanced investment, regional collaboration, and sustained international engagement to effectively mitigate these evolving threats.

• Funding

There was no funding for this study

• Data availability

All data generated or analyzed during this study are included in this article

• Ethics Declarations

• Ethics approval and consent to participate This study does not require ethical approval.

• Consent for publication

Not applicable.

• Clinical Trial Number

Not Applicable

• Competing interests

The author declares no competing interest.

References